Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	11.92B
Revenue (ttm)	425.30M
Net Income (ttm)	-1.25B
Shares Out	154.85M
EPS (ttm)	-8.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,992
Average Volume	170,188
Open	76.00
Previous Close	77.00
Day's Range	75.00 - 76.50
52-Week Range	57.70 - 86.90
Beta	0.73
RSI	64.28
Earnings Date	Aug 12, 2025

About Everi Holdings

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2024, Foresee Pharmaceuticals's revenue was 418.69 million, an increase of 114.67% compared to the previous year's 195.04 million. Losses were -1.08 billion, 4.32% more than in 2023.